Increased Oxidative Stress and Platelet Activation in Patients With Hypertension and Renovascular Disease

Pietro Minuz, MD; Paola Patrignani, PhD; Stefania Gaino, MD; Maurizio Degan, BS; Laura Menapace, MD; Rosamaria Tommasoli, BS; Francesca Seta, DPharm; Marta L. Capone, DPharm; Stefania Tacconelli, DPharm; Simone Palatresi, MD; Chiara Bencini, MD; Cecilia Del Vecchio, MD; Giancarlo Mansueto, MD; Enrico Arosio, MD; Clara Lechi Santonastaso, MD; Alessandro Lechi, MD; Alberto Morganti, MD; Carlo Patrono, MD

Background—Hypertensive patients with renovascular disease (RVD) may be exposed to increased oxidative stress, possibly related to activation of the renin-angiotensin system.

Methods and Results—We measured the urinary excretion of 8-iso-prostaglandin (PG) F$_{2\alpha}$ and 11-dehydro-thromboxane (TX) B$_2$ as indexes of in vivo lipid peroxidation and platelet activation, respectively, in 25 patients with RVD, 25 patients with essential hypertension, and 25 healthy subjects. Plasma renin activity in peripheral and renal veins, angiotensin II in renal veins, cholesterol, glucose, triglycerides, homocysteine, and antioxidant vitamins A, C, and E were also determined. Patients were also studied 6 months after a technically successful angioplasty of the stenotic renal arteries. Urinary 8-iso-PGF$_{2\alpha}$ was significantly higher in patients with RVD (median, 305 pg/mg creatinine; range, 124 to 1224 pg/mg creatinine) than in patients with essential hypertension (median, 176 pg/mg creatinine; range, 48 to 384 pg/mg creatinine) or in healthy subjects (median, 123 pg/mg creatinine; range, 58 to 385 pg/mg creatinine). Urinary 11-dehydro-TXB$_2$ was also significantly higher in RVD patients compared with healthy subjects. In RVD patients, urinary 8-iso-PGF$_{2\alpha}$ correlated with 11-dehydro-TXB$_2$ ($r_s=0.48; P<0.05$) and renal vein renin ($r_s=0.67; P<0.005$) and angiotensin II ($r_s=0.65; P=0.005$) ratios. A reduction in 8-iso-PGF$_{2\alpha}$ after angioplasty was observed in RVD patients with high baseline levels of lipid peroxidation. Changes in 8-iso-PGF$_{2\alpha}$ were related to baseline lipid peroxidation ($r_s=0.73; P<0.001$), renal vein angiotensin II ($r_s=-0.70; P<0.01$) and renin ($r_s=-0.63; P<0.05$) ratios.

Conclusions—Lipid peroxidation is markedly enhanced in hypertensive patients with RVD and is related to activation of the renin-angiotensin system. Moreover, persistent platelet activation triggered or amplified by bioactive isoprostanes may contribute to the progression of cardiovascular and renal damage in this setting. (Circulation. 2002;106:2800-2805.)

Key Words: thromboxane ■ stenosis ■ hypertension ■ renin ■ angiotensin

Renovascular disease (RVD) represents a relatively rare form of secondary hypertension, which in most cases is associated with activation of the renin-angiotensin system as a result of the fall in renal blood flow and perfusion pressure due to renal artery stenosis. RVD is associated with increased cardiovascular mortality and is a major and increasingly prevalent cause of end-stage renal failure. This may be related to increased angiotensin II activity, resulting in vasoconstriction, increased endothelin release, vascular remodeling, extracellular matrix deposition, and accelerated atherogenesis and glomerulosclerosis. These effects may contribute to the progression of cardiovascular and renal damage well beyond the effects of high blood pressure per se.

Increased oxidative stress may occur as a consequence of renal artery stenosis and may play a role in the progression of RVD. Experimental evidence supports this hypothesis and suggests that increased oxidative stress may be related to activation of the renin-angiotensin system. In patients with hypertension and RVD, the pro-oxidant effects of angiotensin II may amplify those due to coexisting metabolic disorders or long-standing hypertension.

In the present study, we investigated whether oxidative stress is enhanced in RVD by measuring the urinary excretion of 8-iso-prostaglandin (PG) F$_{2\alpha}$, a noninvasive index of in vivo lipid peroxidation; 8-iso-PGF$_{2\alpha}$, which is also referred to as iPF$_{2\alpha}$, is a member of the F$_2$-isoprostanes, PG isomers that are formed nonenzymatically through free radical–catalyzed peroxidation of esterified arachidonate in cell membranes and circulating lipoproteins. Enhanced formation of F$_2$-isoprostanes has been reported in association with several...
cardiovascular risk factors and has been found to correlate with in vivo thromboxane (TX) A\textsubscript{2} biosynthesis.\textsuperscript{9-11} 8-Isoprostanes \(\text{F}_{2\alpha}\) are a vasoconstrictor and modulates platelet activation in response to other agonists.\textsuperscript{3} These activities are mediated by the interaction with receptors that are distinct from but closely related to TXA\textsubscript{2}/PGH\textsubscript{2} receptors.\textsuperscript{12} Thus, we tested the hypothesis that angiotensin II–dependent oxidant stress is responsible for enhanced formation of bioactive F\textsubscript{2\alpha}-isoprostanes, resulting in persistent platelet activation in RVD hypertension.

**Methods**

**Subjects**

We studied 25 patients with RVD, 25 subjects with essential hypertension, and 25 healthy subjects (Table 1). Patients were recruited among those admitted to the departments of Internal Medicine of our Institutions. Diagnosis of hypertension associated with RVD was made on the basis of angiographic evidence of renal artery stenosis in patients suspected of having renovascular hypertension on clinical grounds and positive renal scintigraphy and echocardiographic features. Diagnosis of hypertension was supported by the interaction with receptors that are distinct from but closely related to TXA\textsubscript{2}/PGH\textsubscript{2} receptors.\textsuperscript{12} Thus, we tested the hypothesis that angiotensin II–dependent oxidant stress is responsible for enhanced formation of bioactive F\textsubscript{2\alpha}-isoprostanes, resulting in persistent platelet activation in RVD hypertension.

**Table 1. Baseline Characteristics of the Hypertensive Patients and Healthy Subjects**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Healthy Subjects (n = 25)</th>
<th>Essential Hypertensives (n = 25)</th>
<th>RVD Hypertensives (n = 25)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male sex, n (%)</td>
<td>11 (44)</td>
<td>11 (44)</td>
<td>11 (44)</td>
</tr>
<tr>
<td>Age, y</td>
<td>57 (22–69)</td>
<td>64 (30–74)</td>
<td>65 (17–77)</td>
</tr>
<tr>
<td>Cigarette smoking, n (%)</td>
<td>0 (0)</td>
<td>5 (20)</td>
<td>5 (20)</td>
</tr>
<tr>
<td>Diabetes mellitus, n (%)</td>
<td>0 (0)</td>
<td>2 (8)</td>
<td>2 (8)</td>
</tr>
<tr>
<td>Body mass index, kg/m\textsuperscript{2}</td>
<td>23.4 (17.5–30.1)</td>
<td>26.6 (18.4–33.3)</td>
<td>24.8 (18.4–34.4)</td>
</tr>
<tr>
<td>Systolic blood pressure, mm Hg</td>
<td>120 (105–140)</td>
<td>150 (130–185)</td>
<td>165 (110–220)</td>
</tr>
<tr>
<td>Diastolic blood pressure, mm Hg</td>
<td>80 (70–90)</td>
<td>95 (65–110)</td>
<td>90 (65–120)</td>
</tr>
<tr>
<td>PRA, ng/mL per hour</td>
<td>...</td>
<td>0.70 (0.25–4.18)</td>
<td>1.45 (0.25–7.60)</td>
</tr>
<tr>
<td>Glucose, mmol/L</td>
<td>5.38 (4.16–8.54)</td>
<td>5.44 (4.21–6.60)</td>
<td>4.99 (3.88–9.20)</td>
</tr>
<tr>
<td>Total cholesterol, mmol/L</td>
<td>6.15 (4.13–7.70)</td>
<td>5.11 (3.43–7.49)</td>
<td>5.45 (3.59–7.36)</td>
</tr>
<tr>
<td>HDL cholesterol, mmol/L</td>
<td>1.55 (1.19–2.27)</td>
<td>1.34 (0.98–2.09)</td>
<td>1.16 (0.67–2.00)</td>
</tr>
<tr>
<td>Creatinine clearance, mL/min</td>
<td>93 (62–141)</td>
<td>102 (50–147)</td>
<td>60 (19–133)</td>
</tr>
<tr>
<td>Homocysteine, (\mu\text{mol/L})</td>
<td>9.9 (7.1–20.7)</td>
<td>14.1 (8.7–38.0)</td>
<td>15.3 (8.4–40.1)</td>
</tr>
<tr>
<td>Vitamin A, (\mu\text{mol/L})</td>
<td>3.17 (0.31–6.66)</td>
<td>2.93 (0.97–4.59)</td>
<td>3.64 (0.87–7.53)</td>
</tr>
<tr>
<td>Vitamin C, (\mu\text{mol/L})</td>
<td>39.7 (2.5–88.0)</td>
<td>25.5 (2.8–70.9)</td>
<td>29.0 (4.0–81.1)</td>
</tr>
<tr>
<td>Vitamin E, (\mu\text{mol/L})</td>
<td>32.5 (16.2–67.3)</td>
<td>26.2 (14.1–39.4)</td>
<td>23.4 (7.8–38.9)</td>
</tr>
</tbody>
</table>

Data are expressed as median (range) or number (percent). 

\*\(P<0.05\), \(†P<0.01\), \(‡P<0.001\) for essential hypertensives vs healthy subjects. 

\(\S P<0.001\) for RVD hypertensives vs healthy subjects. 

\(\|P<0.05\), \(\&P<0.001\) for RVD hypertensives vs essential hypertensives.
Blood pressure was recorded (the mean of 3 readings) between 10 AM and noon using a mercury column sphygmomanometer with the subjects in the supine position for 30 minutes. Body mass index was also calculated.

The effects of revascularization of the ischemic kidney on lipid peroxidation were evaluated in hypertensive patients with RVD. Blood samples were collected by catheterization from renal veins and the inferior vena cava distal to the ostium of the renal veins (for technical reasons, blood sampling was not done in 4 patients). The renal vein renin ratio (ie, the ratio of PRA in blood draining the stenotic kidney to PRA in venous blood from the contralateral kidney) was used as an index of the activation of the renin-angiotensin system and renal hypoperfusion in patients with unilateral stenosis. Plasma concentration of angiotensin II was also measured in blood from the renal veins and vena cava.

Urine samples were obtained from RVD hypertensives 6 months after revascularization (7 patients were lost to follow-up). Two urine collections and blood sampling were performed 2 days apart according to the previously described procedure (ACE inhibitors and antagonists of the angiotensin receptor were replaced with other antihypertensive drugs at least 15 days in advance). Patency of the treated vessels was evaluated and confirmed by echo-Doppler investigation of the renal arteries 6 months after PTRA.

The study protocol was approved by the ethics committees of the medical centers involved, and informed consent was obtained from all subjects.

Biochemical Analyses

PRA was measured using a radioimmunoassay to quantify the amount of angiotensin-I generated during 1 to 3 hours of incubation of plasma at 37°C and pH 5.7. The sensitivity of the assay was 0.25 ng/mL per hour, and its interassay variability was <11%. Angiotensin II was measured by radioimmunoassay after extraction of the peptide from plasma, as previously described. Immunoactive 8-iso-PGF₂α and 11-dehydro-TXB₂ were extracted from 20-mL urine aliquots and analyzed by previously validated radioimmunoassay techniques. Total homocysteine concentration in plasma was also determined to assess the oxidant-antioxidant balance. Blood was also collected from a peripheral vein to measure plasma renin activity (PRA) in patients with RVD and essential hypertension. Before blood sampling, patients were kept in the supine position for at least 1 hour.

Blood pressure was recorded (the mean of 3 readings) between 10 AM and noon using a mercury column sphygmomanometer with the subjects in the supine position for 30 minutes. Body mass index was also calculated.

The effects of revascularization of the ischemic kidney on lipid peroxidation were evaluated in hypertensive patients with RVD. Blood samples were collected by catheterization from renal veins and the inferior vena cava distal to the ostium of the renal veins (for technical reasons, blood sampling was not done in 4 patients). The renal vein renin ratio (ie, the ratio of PRA in blood draining the stenotic kidney to PRA in venous blood from the contralateral kidney) was used as an index of the activation of the renin-angiotensin system and renal hypoperfusion in patients with unilateral stenosis. Plasma concentration of angiotensin II was also measured in blood from the renal veins and vena cava.

Urine samples were obtained from RVD hypertensives 6 months after revascularization (7 patients were lost to follow-up). Two urine collections and blood sampling were performed 2 days apart according to the previously described procedure (ACE inhibitors and antagonists of the angiotensin receptor were replaced with other antihypertensive drugs at least 15 days in advance). Patency of the treated vessels was evaluated and confirmed by echo-Doppler investigation of the renal arteries 6 months after PTRA.

The study protocol was approved by the ethics committees of the medical centers involved, and informed consent was obtained from all subjects.

Biochemical Analyses

PRA was measured using a radioimmunoassay to quantify the amount of angiotensin-I generated during 1 to 3 hours of incubation of plasma at 37°C and pH 5.7. The sensitivity of the assay was 0.25 ng/mL per hour, and its interassay variability was <11%. Angiotensin II was measured by radioimmunoassay after extraction of the peptide from plasma, as previously described. Immunoactive 8-iso-PGF₂α and 11-dehydro-TXB₂ were extracted from 20-mL urine aliquots and analyzed by previously validated radioimmunoassay techniques. Total homocysteine concentration in plasma was also determined to assess the oxidant-antioxidant balance. Blood was also collected from a peripheral vein to measure plasma renin activity (PRA) in patients with RVD and essential hypertension. Before blood sampling, patients were kept in the supine position for at least 1 hour.

Blood pressure was recorded (the mean of 3 readings) between 10 AM and noon using a mercury column sphygmomanometer with the subjects in the supine position for 30 minutes. Body mass index was also calculated.

The effects of revascularization of the ischemic kidney on lipid peroxidation were evaluated in hypertensive patients with RVD. Blood samples were collected by catheterization from renal veins and the inferior vena cava distal to the ostium of the renal veins (for technical reasons, blood sampling was not done in 4 patients). The renal vein renin ratio (ie, the ratio of PRA in blood draining the stenotic kidney to PRA in venous blood from the contralateral kidney) was used as an index of the activation of the renin-angiotensin system and renal hypoperfusion in patients with unilateral stenosis. Plasma concentration of angiotensin II was also measured in blood from the renal veins and vena cava.

Urine samples were obtained from RVD hypertensives 6 months after revascularization (7 patients were lost to follow-up). Two urine collections and blood sampling were performed 2 days apart according to the previously described procedure (ACE inhibitors and antagonists of the angiotensin receptor were replaced with other antihypertensive drugs at least 15 days in advance). Patency of the treated vessels was evaluated and confirmed by echo-Doppler investigation of the renal arteries 6 months after PTRA.

The study protocol was approved by the ethics committees of the medical centers involved, and informed consent was obtained from all subjects.

Biochemical Analyses

PRA was measured using a radioimmunoassay to quantify the amount of angiotensin-I generated during 1 to 3 hours of incubation of plasma at 37°C and pH 5.7. The sensitivity of the assay was 0.25 ng/mL per hour, and its interassay variability was <11%. Angiotensin II was measured by radioimmunoassay after extraction of the peptide from plasma, as previously described. Immunoactive 8-iso-PGF₂α and 11-dehydro-TXB₂ were extracted from 20-mL urine aliquots and analyzed by previously validated radioimmunoassay techniques. Total homocysteine concentration in plasma was also determined to assess the oxidant-antioxidant balance. Blood was also collected from a peripheral vein to measure plasma renin activity (PRA) in patients with RVD and essential hypertension. Before blood sampling, patients were kept in the supine position for at least 1 hour.

Blood pressure was recorded (the mean of 3 readings) between 10 AM and noon using a mercury column sphygmomanometer with the subjects in the supine position for 30 minutes. Body mass index was also calculated.

The effects of revascularization of the ischemic kidney on lipid peroxidation were evaluated in hypertensive patients with RVD. Blood samples were collected by catheterization from renal veins and the inferior vena cava distal to the ostium of the renal veins (for technical reasons, blood sampling was not done in 4 patients). The renal vein renin ratio (ie, the ratio of PRA in blood draining the stenotic kidney to PRA in venous blood from the contralateral kidney) was used as an index of the activation of the renin-angiotensin system and renal hypoperfusion in patients with unilateral stenosis. Plasma concentration of angiotensin II was also measured in blood from the renal veins and vena cava.

Urine samples were obtained from RVD hypertensives 6 months after revascularization (7 patients were lost to follow-up). Two urine collections and blood sampling were performed 2 days apart according to the previously described procedure (ACE inhibitors and antagonists of the angiotensin receptor were replaced with other antihypertensive drugs at least 15 days in advance). Patency of the treated vessels was evaluated and confirmed by echo-Doppler investigation of the renal arteries 6 months after PTRA.

The study protocol was approved by the ethics committees of the medical centers involved, and informed consent was obtained from all subjects.
As shown in Figure 2, ≈35% of the variability in TX metabolite excretion could be accounted for by the variability in the level of lipid peroxidation in the whole study population. A relationship between 8-iso-PGF$_{2\alpha}$ and 11-dehydro-TXB$_{2}$ was also observed in hypertensive patients with RVD ($r_s=0.48$; n = 20; $P=0.032$).

In RVD patients with unilateral renal artery stenosis, the level of lipid peroxidation correlated significantly with the renal vein renin ratio (Figure 3A) and with the ratio of angiotensin II in blood draining the hypoperfused versus contralateral kidney (Figure 3B). No correlation was found between F$_2$-isoprostane excretion and any of the other studied parameters. Stepwise linear regression analysis identified the renal vein renin ratio as the only variable independently correlated with urinary 8-iso-PGF$_{2\alpha}$ in hypertensive patients with RVD (coefficient $\beta=0.86$; $P<0.001$). In addition, no difference was found in urinary 8-iso-PGF$_{2\alpha}$ excretion among patients with RVD due to fibromuscular dysplasia of the renal arteries, patients with renal artery stenosis due to atherosclerosis, and patients with monolateral or bilateral stenosis (data not shown).

**Effects of Revascularization of the Ischemic Kidneys**

The revascularization procedure had limited effects on blood pressure and renal function (Table 2), and all but 5 patients (3 with fibromuscular dysplasia of renal arteries) required long-term antihypertensive therapy after the procedure, although the number of administered drugs was reduced.

A trend toward reduction in the urinary excretion of 8-iso-PGF$_{2\alpha}$ and 11-dehydro-TXB$_{2}$ was observed after angioplasty (8-iso-PGF$_{2\alpha}$: median, $-66.6$ pg/mg creatinine; range, $-889.3$ to $226.5$ pg/mg creatinine; 11-dehydro-TXB$_{2}$: median, $-284.0$ pg/mg creatinine; range, $-4628$ to $518.0$ pg/mg creatinine). We observed that the variability in individual changes in urinary 8-iso-PGF$_{2\alpha}$ excretion could be largely accounted for by the variable baseline levels of lipid peroxidation (Figure 4). Moreover, the reduction in urinary 8-iso-PGF$_{2\alpha}$ after PTRA was detected in the patients who had baseline values $>300$ pg/mg creatinine (median, $-190.5$ pg/mg creatinine; range, $-889.3$ to $29.0$ pg/mg creatinine; n = 8; $P=0.008$); no significant change was observed in subjects with lower baseline F$_2$-isoprostane excretion (median, $-24.7$ pg/mg creatinine; range, $-87.5$ to $226.5$ pg/mg creatinine; n = 10; $P=0.37$). Changes in 8-iso-PGF$_{2\alpha}$ excretion were also related to baseline values of renal vein renin ratio (Figure 5A), renal vein angiotensin II ratio (Figure 5B), and peripheral PRA ($r_s=-0.61$; n = 18; $P=0.007$). Stepwise multivariate regression analysis identified baseline 8-iso-PGF$_{2\alpha}$ as the only variable independently related to changes in urinary 8-iso-PGF$_{2\alpha}$ after revascularization (coefficient $\beta=-0.81$; $P=0.002$).

**Discussion**

Measurement of the urinary excretion of 8-iso-PGF$_{2\alpha}$ has been characterized as a reliable method of investigating lipid peroxidation in vivo and has been shown to reflect a

![Figure 3](http://circ.ahajournals.org/figure/2801).

**Figure 3.** Correlation between urinary excretion of 8-iso-PGF$_{2\alpha}$ and renal vein renin ratio (A) and correlation between 8-iso-PGF$_{2\alpha}$ and renal vein angiotensin II ratio (B) in 17 hypertensive patients with RVD before revascularization of the ischemic kidney.

![Figure 4](http://circ.ahajournals.org/figure/2802).

**Figure 4.** Changes in urinary 8-iso-PGF$_{2\alpha}$ excretion 6 months after renal artery angioplasty correlate with pretreatment values of 8-iso-PGF$_{2\alpha}$.

![Figure 5](http://circ.ahajournals.org/figure/2803).

**Figure 5.** Changes in urinary 8-iso-PGF$_{2\alpha}$ excretion 6 months after renal artery angioplasty correlate with pretreatment values of renal vein renin ratio (A) and renal vein angiotensin II ratio (B).
status of enhanced oxidative stress, regardless of the underlying pathophysiological triggers. A number of clinical conditions in which increased oxidative stress was postulated on the basis of experimental data or ex vivo tests have been reported to be associated with increased urinary excretion of 8-iso-PGF$_{2\alpha}$.

In the present study, we demonstrated that this noninvasive index of lipid peroxidation is markedly increased in hypertensive patients with RVD compared with patients with essential hypertension with comparable levels of blood pressure and healthy normotensive subjects. A number of coexisting conditions may independently affect the oxidant/antioxidant balance and the level of lipid peroxidation. In our group of RVD hypertensives, the urinary excretion of 8-iso-PGF$_{2\alpha}$ does not seem to be related to the presence of conventional cardiovascular risk factors that may independently be associated with increased oxidative stress: none of them had hypercholesterolemia; moreover, low HDL cholesterol, diabetes mellitus, cigarette smoking, and overt atherosclerosis were equally represented in essential and RVD hypertensives (Table 1). Additional pro-oxidant factors may favor increased lipid peroxidation in hypertensive patients with RVD, such as increased homocysteine and reduced vitamin E plasma concentrations.

However, plasma homocysteine and vitamin E levels were comparable in the 2 groups of hypertensives. Moreover, no correlation existed between urinary 8-iso-PGF$_{2\alpha}$ and either plasma homocysteine or vitamin E.

Increased oxidative stress seemed to be related to renal artery stenosis and activation of the renin-angiotensin system. Our data are consistent with the recent observation that experimental unilateral stenosis of the renal artery in pigs is associated with the development of hypertension and with increased plasma levels of 8-iso-PGF$_{2\alpha}$.

In that experimental setting, the increase in plasma 8-iso-PGF$_{2\alpha}$ correlated with the increase in blood pressure and in PRA after the surgical procedure. The increase in 8-iso-PGF$_{2\alpha}$ was also detected 10 weeks after the induction of renal artery stenosis.

We found a significant positive correlation between 8-iso-PGF$_{2\alpha}$ and renal vein renin ratio. This functional test is a highly specific tool for the detection of renal artery stenosis, renal hypoperfusion, and activation of the renin-angiotensin system; it is also a predictor of the improvement in blood pressure and renal function after revascularization. We also observed that the rate of excreted 8-iso-PGF$_{2\alpha}$ was related to the difference in angiotensin II released from the hypoperfused kidney compared with the contralateral kidney.

The observed relation between the reduction in F$_{2\alpha}$-isoprostane excretion after successful angioplasty in RVD hypertensives with baseline 8-iso-PGF$_{2\alpha}$, angiotensin II ratio, renal vein renin ratio, and peripheral PRA strongly suggests that reversible events associated with renal artery stenosis are responsible for enhanced oxidative stress in this setting. It also provides additional evidence for a causal link between renin activation and lipid peroxidation. These findings may suggest that angiotensin II is the stimulus for isoprostane generation. In vitro and in vivo studies provide different lines of evidence that the hypertensive effect of angiotensin II is associated with the generation of oxygen radical species.

In addition, the infusion of angiotensin II, even at subpressor doses, directly increases superoxide anion and 8-iso-PGF$_{2\alpha}$ generation through a metabolic pathway that involves membrane NADH/NADPH oxidase activity. However, our data do not allow us to assess whether angiotensin II directly stimulates 8-iso-PGF$_{2\alpha}$ generation and whether the source of urinary F$_{2\alpha}$-isoprostanes is located within the ischemic kidney or in the systemic circulation, although the observed relations between urinary 8-iso-PGF$_{2\alpha}$ and both renin ratio and angiotensin II ratio in renal veins suggest that lipid peroxidation may occur primarily in the hypoperfused kidney.

We also investigated the relationship between lipid peroxidation and platelet activation in RVD. Davi et al have described a consistent correlation between urinary excretion rates of 8-iso-PGF$_{2\alpha}$ and 11-dehydro-TXB$_{2}$ in patients with hypercholesterolemia, diabetes mellitus, and homozygous homocystinuria. In addition, further supportive evidence was obtained for a biochemical link between lipid peroxidation and platelet activation in vivo by showing that vitamin E dose-dependently reduced both 8-iso-PGF$_{2\alpha}$ and 11-dehydro-TXB$_{2}$ excretion in these diverse clinical settings.

Consistent with these observations, we found that the rate of TXA$_{2}$ biosynthesis was markedly enhanced in RVD patients and closely correlated with the rate of F$_{2\alpha}$-isoprostane formation.

It is tempting to speculate that increased generation of bioactive F$_{2\alpha}$-isoprostanes and other isoeicosanoids may be responsible, at least in part, for increased platelet activation, the development of hypertension, and ischemic nephropathy in this setting. 8-iso-PGF$_{2\alpha}$ promotes platelet aggregation and induces platelet adhesion. Moreover, 8-iso-PGF$_{2\alpha}$ is a powerful constrictor of the renal vasculature and increases blood pressure. Besides being suggestive of a direct involvement in these functional responses, the increased rate of 8-iso-PGF$_{2\alpha}$ may reflect the presence of more abundant biologically active species formed by similar mechanisms. The hypothesis of a pathophysiological role of increased isoprostane generation is also supported by the observation that TXA$_{2}$/PGH$_{2}$ receptor blockers, but not cyclooxygenase inhibitors, reduced blood pressure in experimental renovascular hypertension.

In conclusion, we have identified RVD with hypertension as a clinical condition characterized by increased lipid peroxidation and platelet activation, presumably as a consequence of renin-angiotensin system activation. The use of ACE inhibitors or angiotensin-receptor antagonists may represent a suitable strategy to probe the pathophysiological role of angiotensin II–dependent lipid peroxidation in this setting.

Acknowledgments

Dr S. Gaino was the recipient of a training grant from the Italian Society for Hypertension. This study was supported by a grant from the Italian Ministry of University and Research to the Center of Excellence on Aging of the University of Chieti. We thank Daniela Basilico for expert editorial assistance and Dr Giorgio Talamini for supervision of the statistical analysis.

References


Increased Oxidative Stress and Platelet Activation in Patients With Hypertension and Renovascular Disease

Pietro Minuz, Paola Patrignani, Stefania Gaino, Maurizio Degan, Laura Menapace, Rosamaria Tommasoli, Francesca Seta, Marta L. Capone, Stefania Tacconelli, Simone Palatresi, Chiara Bencini, Cecilia Del Vecchio, Giancarlo Mansueto, Enrico Arosio, Clara Lechi Santonastaso, Alessandro Lechi, Alberto Morganti and Carlo Patrono

_Circulation_. 2002;106:2800-2805; originally published online November 4, 2002;
doi: 10.1161/01.CIR.0000039528.49161.E9
_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2002 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/106/22/2800

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation_ is online at:
http://circ.ahajournals.org//subscriptions/